TNFSF11 and chronic kidney disease: For example, denosumab effectively inhibits bone resorption by suppressing RANKL; however, it poses a significant risk of hypocalcemia in patients with CKD-MBD, particularly in those who are dialysis-dependent or have advanced CKD (6, 96–98).